Abstract CT099: A phase I study of intralesionalBacillus Calmette-Guerin(BCG) followed by ipilimumab therapy in patients with advanced metastatic melanoma

Background: Immunotherapies with checkpoint inhibitors have revolutionized the treatment of advanced melanomas. Nonetheless, a subset of patients fail to benefit clinically from these immunotherapeutics, and thus strategies aimed at inducing a favorable inflammatory tumor microenvironment prior to immunotherapy are currently being investigated by means of combination therapies. Bacillus Calmette-Guerin (BCG) is a living attenuated strain of...